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EvidEncE-basEd answEr
A 	
	 Does	any	antidepressant		
besides	bupropion	help		
smokers	quit?
	 Yes,	 nortriptyline	 approximately
	 doubles	 smoking	 cessation	 rates,	
an	 effect	 comparable	 to	 bupropion.	Add-
ing	 nortriptyline	 to	 nicotine	 replacement	
therapy	 (NRT)	 doesn’t	 improve	 rates	 fur-
ther	 (strength	 of	 recommendation	 [SOR]:	
A,	 systematic	 review	 of	 randomized	 con-
trolled	trials	[RCTs]).
Selective	 serotonin	 reuptake	 in-
hibitors	 (SSRIs;	 fluoxetine,	 paroxetine,	
sertraline,	citalopram),	venlafaxine,	mono-	
amine	 oxidase	 inhibitors	 (MAOIs;	 mo-
clobemide,	 selegiline),	 doxepin,	 and	 St.	
John’s	wort	don’t	improve	smoking	cessa-
tion	rates	(SOR:	A,	systematic	reviews	and	
RCTs).	
	Evidence summary
Bupropion	is	the	only	Food	and	Drug	Admin-
istration	 (FDA)-approved	 antidepressant	
recommended	as	a	first-line	pharmacologic	
agent	to	assist	with	smoking	cessation,	based	
in	 part	 on	 a	 meta-analysis	 of	 44	 placebo-	
controlled	 RCTs	 (13,728	 patients),	 which	
found	that	bupropion	had	a	relative	risk	(RR)	
of	1.62	for	smoking	cessation	compared	with	
placebo	(95%	confidence	interval	[CI],	1.49-
1.76).	 Bupropion	 produced	 quit	 rates	 that	
were	approximately	double	those	of	placebo	
rates	(18%	[range	4%-43%]	for	bupropion	vs	
9%	[range	0%-18%]	for	placebo).1
Nortriptyline is also effective,  
other antidepressants not so much
A	Cochrane	 systematic	 review	 of	 10	 antide-
pressants	used	for	smoking	cessation	includ-
ed	 64	 placebo-controlled	 trials,	 measuring	
at	 least	 6-month	 abstinence	 rates	 as	 prima-
ry	 outcomes,	 and	 monitoring	 biochemical	
markers	 (such	 as	 breath	 carbon	 monoxide	
and	 urinary	 cotinine)	 to	 verify	 abstinence.	
Some	 trials	 included	 participants	 with	 pre-
vious	 depressive	 episodes,	 but	 most	 didn’t	
enroll	patients	with	active	major	depression.1	
The	 tABLE1	 gives	 an	 overview	 of	 the	 studies	
and	outcomes.
z Nortriptyline, which	 was	 evaluated	
in	 6	 trials,	was	 the	 only	 antidepressant	 be-
sides	bupropion	that	was	superior	to	place-
bo.1	Two	of	 the	nortriptyline	 trials	 included	
participants	with	active	depression	and	the	
other	 trials	 had	 participants	 with	 a	 history	
of	depression.	One	trial	found	no	difference	
in	quit	rates	for	patients	taking	nortriptyline	
with	 or	 without	 a	 history	 of	major	 depres-
sion,	 although	 the	 subgroups	 were	 small.	
Two	trials	measured	quit	rates	for	12	months	
whereas	 the	 other	 4	 trials	 used	 6-month	
quit	rates.	
Four	additional	RCTs	with	1644	patients	
that	combined	nortriptyline	with	NRT	found	
no	improvement	in	quit	rates	compared	with	
NRT	 alone	 (RR=1.21;	 95%	 CI,	 0.94-1.55).1	
Three	RCTs	with	417	patients	compared	bu-
propion	with	nortriptyline	and	found	no	dif-
ference	(RR=1.3;	95%	CI,	0.93-1.8).1
z SSRIs.	None	of	the	4	SSRIs	investigated	
in	 the	 trials	 (fluoxetine,	 paroxetine,	 sertra-
line,	 citalopram)	 improved	 smoking	 cessa-
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tion	rates	more	than	placebo.1	The	5	RCTs	that	
studied	the	drugs	followed	participants	for	as	
long	as	a	year.	None	of	the	participants	were	
depressed	at	the	time	of	the	studies,	although	
some	had	a	history	of	depression.
The	sertraline	RCT	used	individual	coun-
seling	 sessions	 in	 conjunction	 with	 either	
sertraline	 or	 placebo.	 All	 participants	 had	 a	
history	of	major	depression.
The	paroxetine	trial	used	NRT	in	all	pa-
tients	 randomized	 to	 either	 paroxetine	 or	
placebo.	
z Venlafaxine.	 The	 serotonin-norepi-
nephrine	 reuptake	 inhibitor	 venlafaxine	
didn’t	 improve	smoking	cessation	rates	over	
12	months.1	
z MAOIs.	 Neither	 of	 the	 2	 MAOIs	 in-
creased	 smoking	 cessation	 rates.1	The	 mo-
clobemide	 RCT	 followed	 participants	 for	
12	 months;	 the	 5	 selegiline	 RCTs	 followed	
participants	for	as	long	as	6	months.
z Other antidepressants.	 An	 RCT	 with	
19	 participants	 found	 that	 doxepin	 didn’t	
improve	 smoking	 cessation	 at	 2	 months.1	
One	RCT	and	one	open,	randomized	trial	of	
St.	John’s	wort	found	no	benefit	for	smoking	
cessation.1,2
Recommendations
The	 United	 States	 Public	 Health	 Service	
(USPHS)	 and	 the	 University	 of	 Michigan	
Health	 System	 (UMHS)	 guidelines	 recom-
mend	 the	 following	FDA-approved	pharma-
cotherapies	 as	 first-line	 agents	 for	 smoking	
cessation:	 sustained-release	 bupropion,	
NRT	 (gum,	 inhaler,	 lozenge,	 nasal	 spray,	 or	
patch),	and	varenicline.3,4	They	say	that	cloni-
dine	 and	nortriptyline	 are	 also	 effective	 but	
recommend	them	as	second-line	agents	be-
cause	these	drugs	lack	FDA	approval	for	this	
purpose.
The	USPHS	also	recommends	combina-
tions	 of	 NRT	 and	 bupropion	 for	 long-term	
use.	 Because	 of	 additional	 cost	 and	 limited	
benefit,	UMHS	recommends	reserving	NRT-
bupropion	 combination	 therapy	 for	 highly	
addicted	 tobacco	 users	 who	 have	 several	
failed	quit	attempts.
The	 United	 States	 Preventive	 Services	
Task	Force	guideline	emphasizes	counseling	
and	 interventions	 to	prevent	 tobacco	use;	 it	
doesn’t	 provide	 recommendations	 for	phar-
macotherapy.5	 It	 does	 cite	 the	 same	 agents	
recommended	 by	 USPHS	 and	 UMHS	 as	
effective.			 	 	 														JFP
tABLE
Antidepressants	for	smoking	cessation:		
Quit	rates	compared	with	placebo1
antidepressant Dose rcTs, N Patients, N rr (for smoking 
cessation)
95% cI
bupropion 150 mg twice 
daily
44 13,728 1.62 1.49-1.76
Nortriptyline 75-100 mg/d 6 975 2.03 1.48-2.78
Fluoxetine 20-60 mg/d 2 1236 0.92* 0.65-1.30
Paroxetine 20-40 mg/d 1 224 1.08* 0.64-1.82
Sertraline 200 mg/d 1 134 0.71* 0.30-1.64
citalopram 20-40 mg/d 1 17 0.68* Not available
venlafaxine 225 mg/d 1 147 1.22* 0.64-2.32
moclobemide 200-400 mg/d 1 88 1.57* 0.67-3.68
Selegiline 10 mg/d 5 739 1.25* 0.88-1.78
Doxepin 150 mg/d 1 19 No benefit Not applicable
St. John’s wort 300-600 mg/d 2 261 0.81* 0.26-2.53
cI, confidence interval; rcTs, randomized controlled trials; rr, relative risk.
*Not statistically significant.
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Medical Director
Department of Family Medicine
Wayne State University Physician Group
The	Wayne	State	University	Physician	Group	(WSUPG)	Department	of	Family	Medicine	is	seeking	a	Medical	Director	to	supervise	
clinical	operations	at	our	residency	Family	Medicine	Center	located	in	beautiful	Rochester	Hills,	Michigan.	Our	clinical	practice	in-
cludes	a	15,000	square	foot	newly	constructed	state-of-the-art	academic	medical	center,	which	serves	as	the	primary	site	for	residency	
education.	The	Medical	Director	will	be	responsible	for	compliance	with	quality	measures,	and	have	in-depth	knowledge	of	PCMH,	
NCQA,	and	HEDIS.	The	Medical	Director	will	monitor	clinic	performance	targets	and	metrics,	supervise	standards	of	care,	assist	in	
implementing	processes	that	improve	clinical	outcomes	for	our	patients,	and	model	best	practices.	The	Medical	Director	will	have	
knowledge	of	residency	education	and	ACGME	requirements	consistent	with	a	faculty	appointment.
As	one	of	the	largest	Physician	Practice	Groups	in	Southeast	Michigan	with	more	than	2,000	affiliated	physicians,	representing	over		
30	specialties,	WSUPG	Offers:
•		Commitment	to	practice	supports	across	the	care	continuum
•		Exceptional	compensation	geared	toward	an	ACO	model
•		A	focus	on	quality,	panel	size	and	coordination	of	care,	not	just	productivity
•		Integrated	EMR/Provider/Patient	Portal
•		Highly	Competitive	Salary
•		A	Strong	benefits	package	including	employer	retirement	contributions
•		Malpractice	insurance	which	includes	tail	coverage
A	selected	candidate	will	be	licensed	in	the	State	of	Michigan,	a	graduate	of	an	ACGME/AOA	accredited	residency	program	and	ABFM	
board	certified/board	eligible.	Experience	teaching	in	academic	setting	and	will	hold	a	Faculty	rank	commensurate	with	credentials.	
Have	a	minimum	of	5	years’	experience	supervising	a	Family	Medicine	clinical	practice	as	well	as	having	familiarity	with	Graduate	
Medical	Education	processes.
E.O.E.
If you are interested in joining our team of physicians, committed to providing top quality and compassionate care,  
please forward CV and cover letter:
Tsveti Markova, MD, FAAFP
Wayne State University Physician Group
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